Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Olema Pharmaceuticals Inc OLMA

Healthcare Biotechnology
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an... see more

Recent & Breaking News (NDAQ:OLMA)

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 5, 2022

Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program

GlobeNewswire June 9, 2022

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

GlobeNewswire June 9, 2022

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire June 2, 2022

Olema Oncology to Present at Jefferies Healthcare Conference

GlobeNewswire May 24, 2022

Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2022

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2022

Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 18, 2022

Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire April 4, 2022

Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022

GlobeNewswire March 8, 2022

Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire February 28, 2022

Olema Oncology to Present at Cowen 42nd Annual Health Care Conference

GlobeNewswire February 22, 2022

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 3, 2022

Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer

GlobeNewswire January 31, 2022

Olema Oncology to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Olema Oncology Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer

GlobeNewswire November 30, 2021

Olema Oncology Issues Statement Regarding Falsified Information Circulating on Social Media

GlobeNewswire November 29, 2021

Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium

GlobeNewswire November 22, 2021

Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2021

Olema Oncology to Present at Two Upcoming Investor Conferences

GlobeNewswire November 9, 2021